14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TAK vs HIMS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
TAK Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)
TAK Overall Winner
6-Pillar Tally: TAK 5 – 1 HIMS
Matrix Metrics: TAK 7 – 3 HIMS
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Hims & Hers Health, Inc. (HIMS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas HIMS carries 53.5/100 (HOLD) at $18.91 (54.0x Forward P/E, -6.4% operating margin).
Composite vs. Pillar Nuance: While HIMS currently prints a higher short-term Unified Composite Score (53.5/100 HOLD vs. TAK 47.7/100 HOLD), TAK captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (16.6% vs. -6.4% operating margin) and revenue trajectory (+6.7% vs. +48.6% YoY).
Technical & Structure Timing Caution: TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 73.1); meanwhile HIMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs HIMS. Trailing 12-month operating profitability (TAK 16.6% vs HIMS -6.4%) and valuation multiples (TAK 12.7x vs HIMS 54.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $4.6B market capitalization and -6.4% operating margin.
OpEx & R&D Reinvestment71.2% of Rev ($2.04B)
90D Engineering Disclosures0 Published
Investor FAQ TAK vs HIMS Key Questions & Quantitative Answers
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Hims & Hers Health, Inc. (HIMS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas HIMS carries 53.5/100 (HOLD) at $18.91 (54.0x Forward P/E, -6.4% operating margin). Composite vs. Pillar Nuance: While HIMS currently prints a higher short-term Unified Composite Score (53.5/100 HOLD vs. TAK 47.7/100 HOLD), TAK captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (16.6% vs. -6.4% operating margin) and revenue trajectory (+6.7% vs. +48.6% YoY). Technical & Structure Timing Caution: TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 73.1); meanwhile HIMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TAK leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with HIMS at +48.6% YoY revenue growth and -17.4% YoY earnings growth on $2.87B TTM revenue (64.8% gross margin, -6.4% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $2.87B for HIMS. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 71.2% of Rev ($2.04B) (0 disclosures) for HIMS.
TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas HIMS trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.90x PEG, and 1.9x EV/Revenue (0.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus HIMS (-40.8% ROE) capital efficiency.
In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, HIMS carries 68.0% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.38x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.61β · 103% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.